Side-by-Side Comparison
BPC-157 vs Ipamorelin: Mechanism, Evidence & Safety Compared
An evidence-based side-by-side look at how BPC-157 and Ipamorelin differ in mechanism, regulatory status, strength of the research base, and clinical application — compiled from the published literature and the FDA regulatory record.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
BPC-157
L2Also: Body Protection Compound-157, Bepecin, PL 14736
A gastric pentadecapeptide studied extensively in animal models for tissue healing, gut protection, and cytoprotective properties. Despite over 100 preclinical studies, human clinical data remains extremely limited.
Also: NNC 26-0161
A selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin.
Side-by-side comparison
| Attribute | BPC-157 | Ipamorelin |
|---|---|---|
| Primary mechanism | Angiogenesis & VEGF Modulation | Ghrelin Receptor Agonism |
| FDA status | Banned from Compounding (Category 2) | Banned from Compounding (Category 2) |
| Evidence level | Preclinical Evidence | Emerging Clinical Evidence |
| Human trials | Yes (3+ indexed) | Yes (2+ indexed) |
| Studies indexed | 128 total (3 human, 95 animal) | 33 total (4 human, 18 animal) |
| Primary uses researched | Tissue repair, Gut healing, Tendon recovery, Anti-inflammatory, Wound healing, Neuroprotection | Growth hormone release, Body composition, Sleep quality, Recovery |
| Administration routes | intramuscular, intraperitoneal (research), oral, subcutaneous, topical | subcutaneous |
| Molecular weight | 1419.53 Da | 711.85 Da |
| Amino acids | 15 | 5 |
| Category | healing recovery | growth hormone |
| WADA status | Prohibited | Prohibited |
Key differences
Mechanism. BPC-157 acts primarily through angiogenesis & vegf modulation, while Ipamorelin acts primarily through ghrelin receptor agonism. This means they address different biological pathways even when targeting overlapping clinical goals.
Regulatory status. Both compounds share the same FDA status (Banned from Compounding (Category 2)), which means the practical pathway to access is similar for each.
Evidence base. Ipamorelin sits at a higher evidence level (L3) than BPC-157 (L2) under PeptideMark's L1–L5 methodology.
Research focus. Published research on BPC-157 has concentrated on tissue repair, gut healing, tendon recovery. Research on Ipamorelin has concentrated on growth hormone release, body composition, sleep quality. These research programs have limited overlap, and comparisons are most useful when readers are evaluating adjacent therapeutic goals.
Safety snapshot
| Attribute | BPC-157 | Ipamorelin |
|---|---|---|
| Documented effects | 7 total | 6 total |
| Serious events | 0 | 0 |
| Common events | 1 | 1 |
| Black box warning | No | No |
| Contraindications | 3 listed | 3 listed |
| Drug interactions | 3 flagged | 2 flagged |
| Most common event | Injection site reactions | Injection site reactions |
Strengths & limitations
BPC-157
Strengths
- Represents an area of active research interest with growing study volume
Limitations
- Restricted from compounding pharmacies (FDA Category 2)
- Limited evidence base (L2)
- Prohibited in competitive sport under WADA
Ipamorelin
Strengths
- Represents an area of active research interest with growing study volume
Limitations
- Restricted from compounding pharmacies (FDA Category 2)
- Few human trials — most data is preclinical
- Prohibited in competitive sport under WADA
Representative studies
BPC-157
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review
Vasireddi N, Hahamyan H, Salata MJ, et al. · Sports Health (2025)
Despite broad preclinical support across muscle, tendon, ligament, and bone models, only one clinical study exists for musculoskeletal applications, leaving a significant gap between animal and human evidence.
PubMed 40756949Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study
Lee KY, Burgess MM. · Alternative Therapies in Health and Medicine (2025)
Intravenous BPC-157 up to 20mg was well-tolerated in 2 healthy adults with no measurable effects on heart, liver, kidney, thyroid, or glucose biomarkers. Plasma levels returned to baseline within 24 hours.
PubMed 40131143Ipamorelin
Ipamorelin, a new growth-hormone-releasing peptide, induces growth hormone release in a specific and selective manner
Raun K, Hansen BS, Johansen NL, et al. · Journal of Endocrinology (1998)
Ipamorelin demonstrated true GH selectivity: no cortisol/ACTH/prolactin elevation even at supramaximal doses, establishing it as the cleanest GHRP.
PubMed 9725926Ipamorelin, the first selective growth hormone secretagogue
Johansen PB, Nowak J, Skjærbæk C, et al. · European Journal of Endocrinology (1999)
Confirmed ipamorelin as the first truly selective GH secretagogue, with a selectivity window exceeding 200-fold between GH release and cortisol stimulation.
PubMed 10580762Frequently asked
What is the main difference between BPC-157 and Ipamorelin?
BPC-157 is a gastric pentadecapeptide studied extensively in animal models for tissue healing, gut protection, and cytoprotective properties. despite over 100 preclinical studies, human clinical data remains extremely limited. Its primary mechanism is angiogenesis & vegf modulation. Ipamorelin is a selective growth hormone secretagogue that stimulates gh release without significantly affecting cortisol or prolactin. Its primary mechanism is ghrelin receptor agonism. The two differ in regulatory status (Banned from Compounding (Category 2) vs Banned from Compounding (Category 2)), strength of evidence (L2 vs L3), and the primary conditions for which each is researched.
Is BPC-157 or Ipamorelin FDA approved?
BPC-157: BPC-157 was placed on the FDA Category 2 list (substances with safety concerns) in late 2023, prohibiting compounding pharmacies from producing it for human use under Section 503A. The FDA cited potential immune reactions, manufacturing impurities, and a lack of human safety data. BPC-157 is not FDA-approved for any human indication. There is no legal basis for selling it as a drug, food, or dietary supplement. The FDA has stated it may take enforcement action against compounding pharmacies that produce it. Several legal challenges to the Category 2 classification are ongoing. Ipamorelin: Placed on FDA Category 2 list in late 2023. Not approved for human use.
How does the evidence base compare?
BPC-157 has 128 indexed studies (3 human, 95 animal) and is rated Preclinical Evidence. Ipamorelin has 33 indexed studies (4 human, 18 animal) and is rated Emerging Clinical Evidence. Evidence ratings reflect PeptideMark's L1–L5 methodology based on study type, sample size, and replication.
Can BPC-157 and Ipamorelin be compared directly?
BPC-157 and Ipamorelin come from different therapeutic categories (healing recovery vs growth hormone), so direct clinical comparison is limited. Readers often compare them because of overlapping research interest, shared patient populations, or adjacent mechanisms — not because head-to-head trial data exists.
Are BPC-157 and Ipamorelin commonly stacked together?
There is no widely documented stacking protocol combining BPC-157 and Ipamorelin in the peer-reviewed literature. Any combination use should be supervised by a qualified clinician familiar with both compounds' pharmacology and contraindications.
Which has a better-documented safety profile, BPC-157 or Ipamorelin?
BPC-157 has 7 documented side effects (0 serious). Ipamorelin has 6 documented side effects (0 serious). Better documentation does not necessarily mean safer — FDA-approved drugs have more rigorous adverse-event reporting, while research-only compounds may appear "cleaner" simply because fewer controlled trials have captured events systematically.
How are BPC-157 and Ipamorelin administered?
BPC-157 is typically administered via intramuscular or intraperitoneal (research) or oral or subcutaneous or topical. Ipamorelin is typically administered via subcutaneous. Route differences affect onset, peak levels, and patient convenience.
Which is better, BPC-157 or Ipamorelin?
"Better" depends on the therapeutic goal, regulatory context, and individual response. BPC-157 is most researched for tissue repair and gut healing; Ipamorelin is most researched for growth hormone release and body composition. FDA status also matters: Banned from Compounding (Category 2) for BPC-157 vs Banned from Compounding (Category 2) for Ipamorelin. This page is educational — any decision to use either compound should be made with a qualified clinician who has reviewed your medical history.
Related comparisons
Full profile
BPC-157 →
Full profile
Ipamorelin →